Oncogenic RET Fusions: Biology, Testing, and Treatment

Free for members and $29 for nonmembers

This interactive live webinar is part 15 of the Emerging and Evolving Biomarkers Series


In this webinar, we will focus on the biology, testing strategies and treatment implications for tumors with oncogenic RET fusions. RET (REarranged during Transfection) protein is a transmembrane receptor tyrosine kinase that is encoded by the RET gene and plays an important role in the development of the nervous system. In cancer, RET signaling can be dysregulated through chromosomal rearrangements that result in the fusion of the 3’ RET tyrosine kinase domain with a different 5’ partner gene, leading to constitutive activation of RET kinase domain and subsequent oncogene addiction. While these oncogenic RET fusions are rare, there are now highly effective RET targeted therapies that have been FDA-approved for all advanced solid tumors with oncogenic RET fusions regardless of histology, underscoring the growing need for accurate and sensitive detection of these actionable biomarkers in the clinic. 

Learning Objectives:

  • Review the biology, pathogenicity, and epidemiology of oncogenic RET fusions across different cancer types
  • Discuss various clinical-grade assays and testing strategies for detecting RET fusions, including advantages and limitations for each method
  • Understand the therapeutic significance of RET fusions as a pan-cancer predictive biomarker

Soo-Ryum Yang, MD

Fei Dong, MD

Duration: 1 Hour
Level of Instruction: Intermediate
Live webinar: March 14, 2024
Date Recorded: March 14, 2024

How to Register:
  1. Click the "Register Now" Button
  2. Log in using your AMP credentials. If you do not have an AMP account, Create a FREE account.
  3. Complete the "Demographic questionnaire for Emerging and Evolving Biomarkers Series" before the webinar date. You will only need to do this once for the entire series.

Continuing Education Credit Information

CME credit: 1.0
CMLE credit: 1.0 
Last day to claim credit: December 31, 2026

Accreditation Statements
AMA PRA Category 1 Credit(s)
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Society for Clinical Pathology (ASCP) and Association for Molecular Pathology (AMP). The American Society for Clinical Pathology (ASCP) is accredited by the ACCME to provide continuing medical education for physicians.

The ASCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology for 1.0 hours of CMLE credit. ASCP CMLE credit hours are acceptable for the ASCP Board of Certification (BOC) Certification Maintenance Program (CMP). CMLE credit hours meet the continuing education requirements for the ASCP Board of Certification Credential Maintenance Program (CMP) and state relicensure requirements for laboratory personnel. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Note: Join the AMP Family for discounted access to the most current educational resources!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentation.

*NEW* Nonmembers may register for this webinar for $29
AMP Members may register for free